205 related articles for article (PubMed ID: 27789107)
1. Successful Treatment of Iron-Overload Cardiomyopathy in Hereditary Hemochromatosis With Deferoxamine and Deferiprone.
Tauchenová L; Křížová B; Kubánek M; Fraňková S; Melenovský V; Tintěra J; Kautznerová D; Malušková J; Jirsa M; Kautzner J
Can J Cardiol; 2016 Dec; 32(12):1574.e1-1574.e3. PubMed ID: 27789107
[TBL] [Abstract][Full Text] [Related]
2. On myocardial siderosis and left ventricular dysfunction in hemochromatosis.
Carpenter JP; Grasso AE; Porter JB; Shah F; Dooley J; Pennell DJ
J Cardiovasc Magn Reson; 2013 Mar; 15(1):24. PubMed ID: 23509881
[TBL] [Abstract][Full Text] [Related]
3. Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH).
Fabio G; Minonzio F; Delbini P; Bianchi A; Cappellini MD
Blood; 2007 Jan; 109(1):362-4. PubMed ID: 16960153
[TBL] [Abstract][Full Text] [Related]
4. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
Kolnagou A; Michaelides Y; Kontos C; Kyriacou K; Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):17-28. PubMed ID: 18274979
[TBL] [Abstract][Full Text] [Related]
5. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
[TBL] [Abstract][Full Text] [Related]
6. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):219-27. PubMed ID: 16798647
[TBL] [Abstract][Full Text] [Related]
7. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
Kolnagou A; Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):239-49. PubMed ID: 16798649
[TBL] [Abstract][Full Text] [Related]
8. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
Kolnagou A; Kleanthous M; Kontoghiorghes GJ
Eur J Haematol; 2010 Nov; 85(5):430-8. PubMed ID: 20662901
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
[TBL] [Abstract][Full Text] [Related]
10. Combined therapy with deferoxamine and deferiprone.
Kattamis A
Ann N Y Acad Sci; 2005; 1054():175-82. PubMed ID: 16339663
[TBL] [Abstract][Full Text] [Related]
11. Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy.
Bring P; Partovi N; Ford JA; Yoshida EM
Pharmacotherapy; 2008 Mar; 28(3):331-42. PubMed ID: 18294113
[TBL] [Abstract][Full Text] [Related]
12. T2* magnetic resonance and myocardial iron in thalassemia.
Pennell DJ
Ann N Y Acad Sci; 2005; 1054():373-8. PubMed ID: 16339685
[TBL] [Abstract][Full Text] [Related]
13. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
[TBL] [Abstract][Full Text] [Related]
14. Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
Cassinerio E; Roghi A; Pedrotti P; Brevi F; Zanaboni L; Graziadei G; Pattoneri P; Milazzo A; Cappellini MD
Ann Hematol; 2012 Sep; 91(9):1443-9. PubMed ID: 22572843
[TBL] [Abstract][Full Text] [Related]
15. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
16. Iron chelation therapy in the management of transfusion-related cardiac iron overload.
Fernandes JL
Transfusion; 2012 Oct; 52(10):2256-68. PubMed ID: 22404719
[TBL] [Abstract][Full Text] [Related]
17. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.
Peng CT; Tsai CH; Wu KH
Hemoglobin; 2008; 32(1-2):49-62. PubMed ID: 18274983
[TBL] [Abstract][Full Text] [Related]
18. Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment.
Murphy CJ; Oudit GY
J Card Fail; 2010 Nov; 16(11):888-900. PubMed ID: 21055653
[TBL] [Abstract][Full Text] [Related]
19. Cardiac iron overload following liver transplantation in patients without hereditary hemochromatosis or severe hepatic iron deposition.
Papadodima S; Masia R; Stone JR
Cardiovasc Pathol; 2019; 40():7-11. PubMed ID: 30763826
[TBL] [Abstract][Full Text] [Related]
20. Improvement in Left Ventricular Function Despite No Change in T2* with Iron Chelation in Secondary Hemochromatosis.
Nijjar PS; Vongooru H; Tamene A; Valeti U; Masri C
Minn Med; 2015 Jul; 98(7):47. PubMed ID: 26267924
[No Abstract] [Full Text] [Related]
[Next] [New Search]
